Literature DB >> 33255200

Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature.

Bruno Corrado1, Gianluca Ciardi1, Laura Lucignano1.   

Abstract

OBJECTIVE: to find the most up-to-date evidence of the effectiveness and safety of supervised physical therapy in polymyositis/dermatomyositis patients.
METHODS: a systematic review of the literature in the main scientific databases was carried out. We searched for randomized controlled trials concerning supervised physical therapy and polymyositis/dermatomyositis. The PICOS method was used for the formulation of the clinical query. Methodological quality and the level of evidence of the included studies were assessed using the modified Jadad scale and the Oxford Centre for Evidence-Based Medicine Levels of Evidence guide, respectively.
RESULTS: a total of 2591 articles were found. By applying the inclusion/exclusion criteria, six randomized controlled clinical trials were admitted to the final phase of the review. The compared approaches concerned supervised exercise programs based on strategies of muscle strengthening or aerobic work. Following these exercises, an increase in the maximum rate of oxygen consumption, a decrease in creatine phosphokinase levels, an enhancement in the patient's aerobic performance and an improvement in the quality of life indexes were registered. The methodological quality of the included studies ranged from 3 to 4.5. All the studies were classified as presenting an evidence level of 2b.
CONCLUSIONS: supervised physical therapy in polymyositis/dermatomyositis is an effective, safe and free-of-contraindications tool to be used both in the acute and in the established phases of the pathology. However, further and higher-quality studies are necessary to confirm those findings, to clarify the timing of exercise delivery and to guide the choice towards different types of muscle contraction exercises.

Entities:  

Keywords:  dermatomyositis; physical therapy; polymyositis; quality of life; rehabilitation

Year:  2020        PMID: 33255200      PMCID: PMC7768488          DOI: 10.3390/neurolint12030015

Source DB:  PubMed          Journal:  Neurol Int        ISSN: 2035-8385


  44 in total

Review 1.  An overview of polymyositis and dermatomyositis.

Authors:  Andrew R Findlay; Namita A Goyal; Tahseen Mozaffar
Journal:  Muscle Nerve       Date:  2015-05       Impact factor: 3.217

Review 2.  Osteoporosis and rheumatic diseases.

Authors:  N Maruotti; A Corrado; F P Cantatore
Journal:  Reumatismo       Date:  2014-06-28

3.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

4.  Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme.

Authors:  G F Wiesinger; M Quittan; M Aringer; A Seeber; B Volc-Platzer; J Smolen; W Graninger
Journal:  Br J Rheumatol       Date:  1998-02

5.  Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis -- a randomized controlled single-blinded study with a 2-year followup.

Authors:  Helene Alexanderson; Li Alemo Munters; Maryam Dastmalchi; Ingela Loell; Mikael Heimbürger; Christina H Opava; Ingrid E Lundberg
Journal:  J Rheumatol       Date:  2014-05-01       Impact factor: 4.666

6.  Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial.

Authors:  Vincent Tiffreau; François Rannou; François Kopciuch; Eric Hachulla; Luc Mouthon; Philippe Thoumie; Jean Sibilia; Elodie Drumez; André Thevenon
Journal:  Arch Phys Med Rehabil       Date:  2016-10-24       Impact factor: 3.966

7.  Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup.

Authors:  Li Alemo Munters; Maryam Dastmalchi; Vivianne Andgren; Christina Emilson; Jenny Bergegård; Malin Regardt; Anna Johansson; Ingrid Orefelt Tholander; Balsam Hanna; Maria Lidén; Mona Esbjörnsson; Helene Alexanderson
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

8.  A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Authors:  Brandon W Higgs; Wei Zhu; Chris Morehouse; Wendy I White; Philip Brohawn; Xiang Guo; Marlon Rebelatto; Chenxiong Le; Anthony Amato; David Fiorentino; Steven A Greenberg; Jorn Drappa; Laura Richman; Warren Greth; Bahija Jallal; Yihong Yao
Journal:  Ann Rheum Dis       Date:  2013-02-23       Impact factor: 19.103

9.  Rehabilitation management of Pompe disease, from childhood trough adulthood: A systematic review of the literature.

Authors:  Bruno Corrado; Gianluca Ciardi; Clemente Servodio Iammarrone
Journal:  Neurol Int       Date:  2019-06-18

10.  Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis.

Authors:  Li Alemo Munters; Maryam Dastmalchi; Abram Katz; Mona Esbjörnsson; Ingela Loell; Balsam Hanna; Maria Lidén; Håkan Westerblad; Ingrid E Lundberg; Helene Alexanderson
Journal:  Arthritis Res Ther       Date:  2013-08-13       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.